Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

Feature
November 1, 2013 — A study found that both drug-eluting stents (DES) with biocompatible polymers and DES with ...
Home November 01, 2013
Home
News
October 31, 2013 — Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate ...
Home October 31, 2013
Home
News
October 29, 2013 — Biotronik Japan announced enrollment of the first patient in the Bioflow-IV study, which aims to ...
Home October 29, 2013
Home
News
October 28, 2013 — Biosensors International’s expanded product portfolio offers physicians a broader range of treatment ...
Home October 28, 2013
Home
News

September 27, 2013 — Patient enrollment has been initiated in a post-market registry for the COMBO Dual Therapy Stent to ...

Home September 27, 2013
Home
News

September 17, 2013 — In a significant milestone toward obtaining additional key regulatory approvals for the Synergy dru ...

Home September 17, 2013
Home
News

August 19, 2013 — Cook Medical is again shipping its Zilver PTX drug-eluting peripheral stent to medical centers in the ...

Home August 19, 2013
Home
News

August 16, 2013 — Patient enrollment has been initiated in a post-market registry for the Combo Dual Therapy Stent to ...

Home August 16, 2013
Home
News

July 1, 2013 — Primary end-point results from the BIOFLOW-II clinical study demonstrating the non-inferiority of the ...

Home July 01, 2013
Home
News

June 24, 2013 — Final six and 12-month results of the DIRECT first-in-man clinical study were presented by study ...

Home June 24, 2013
Home
News

June 11, 2013 — New long-term data from the DIVERGE clinical study, presented at EuroPCR 2013 by Principal Investigator ...

Home June 11, 2013
Home
News

May 28, 2013 — Abbott announced CE mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System ...

Home May 28, 2013
Home
News

April 30, 2013 — Cook Medical has initiated a global voluntary recall of its Zilver PTX Drug Eluting Peripheral Stent ba ...

Home April 30, 2013
Home
News

March 28, 2013 — Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug ...

Home March 28, 2013
Home
News

March 20, 2013 — Svelte Medical Systems announced treatment of the first patient in the DIRECT II (Direct Implantation ...

Home March 20, 2013
Home
Subscribe Now